Eidos Therapeutics initiated with a Buy at Roth Capital. Roth Capital analyst Yasmeen Rahimi started Eidos Therapeutics with a Buy rating and $28 price target. The analyst notes that the company’s Phase 2 results are anticipated at the AHA meeting on November 10, and views AG10 as a best-in-class transthyretin stabilizer for treatment of ATTR-CM.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.